Barclays PLC Has $645,000 Position in MaxCyte, Inc. (NASDAQ:MXCT)

Barclays PLC lifted its stake in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 329.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 165,765 shares of the company's stock after purchasing an additional 127,156 shares during the period. Barclays PLC owned approximately 0.16% of MaxCyte worth $645,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of MXCT. Intech Investment Management LLC acquired a new stake in MaxCyte during the 3rd quarter worth about $51,000. China Universal Asset Management Co. Ltd. increased its position in shares of MaxCyte by 64.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 20,212 shares of the company's stock worth $79,000 after acquiring an additional 7,930 shares in the last quarter. Verition Fund Management LLC raised its holdings in shares of MaxCyte by 39.5% during the third quarter. Verition Fund Management LLC now owns 21,335 shares of the company's stock valued at $83,000 after acquiring an additional 6,045 shares during the period. Creative Planning lifted its position in shares of MaxCyte by 33.6% in the 3rd quarter. Creative Planning now owns 28,652 shares of the company's stock valued at $111,000 after acquiring an additional 7,212 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in MaxCyte by 84.5% in the 3rd quarter. SG Americas Securities LLC now owns 37,969 shares of the company's stock worth $148,000 after purchasing an additional 17,385 shares during the period. 68.81% of the stock is owned by hedge funds and other institutional investors.

MaxCyte Trading Up 4.0 %

NASDAQ:MXCT traded up $0.19 during trading hours on Friday, hitting $4.94. 648,042 shares of the stock traded hands, compared to its average volume of 673,322. The firm has a 50 day moving average price of $3.98 and a 200 day moving average price of $4.04. The firm has a market cap of $522.21 million, a price-to-earnings ratio of -14.53 and a beta of 1.29. MaxCyte, Inc. has a fifty-two week low of $3.16 and a fifty-two week high of $5.32.

MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. The business had revenue of $8.16 million for the quarter, compared to the consensus estimate of $7.50 million. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. During the same quarter in the previous year, the company posted ($0.11) earnings per share. Research analysts predict that MaxCyte, Inc. will post -0.42 EPS for the current year.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.